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Our work focuses on genetic and molecular mechanisms for the reciprocal regulation
of bone and energy metabolism orchestrated by leptin and osteocalcin. In the context of
this reciprocal regulation, the finding that leptin inhibits insulin secretion by β cells while
osteocalcin favors it is surprising. In exploring the molecular bases of this paradox we
found that leptin, as is the case for most of its functions, uses a neuronal relay to inhibit
insulin secretion. Cell-specific gene-deletion experiments revealed that a component
of this neuronal regulation is the sympathetic innervation to osteoblasts. Under the
control of leptin the sympathetic tone favors expression in osteoblasts of Esp, which
inhibits the metabolic activity of osteocalcin. We further identify ATF4 as a transcription
factor that regulates Esp expression and thereby insulin secretion and sensitivity. Taken
together these data illustrate the tight connections between bone remodeling and energy
metabolism and add further credence to the notion that the osteoblast is a bona fide
endocrine cell type.
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Leptin inhibits insulin secretion in part through
a well-established direct effect on β-cells1,2 and
in part through indirect mechanisms that have
not been fully elucidated.1–4 Since hyperin-
sulinemia is observed in both leptin-deficient
(ob/ob) and lipodystrophic (adipocyte-deficient)
states,5–7 we used ob/ob, adipocyte-deficient,
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and other mouse models with perturbed leptin
signaling to determine which indirect mecha-
nisms contribute to leptin regulation of insulin
secretion.
Ob/ob mice were analyzed at birth and 1
and 2 weeks of age because at those ages body
weight, fat mass, triglyceride level, and insulin
sensitivity are not noticeably altered by the ab-
sence of leptin (Fig. 1A and B and Fig. S1). Thus,
young ob/ob mice constitute a good genetic
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Figure 1. Leptin regulates, in part, insulin secretion through hypothalamic neuronal pathway. Insulin
expression and secretion and β-cell proliferation in ob/ob (A to F) and adipocyte-deficient (adp-def) mice at
indicated ages (G to N). (A and G) Body weight. (B and H) Fat mass. (C and I) Serum insulin levels. (D
and J) Blood glucose levels. (E and K) Gene expression in pancreas or islets. (F and L to N) Insulin/Ki67-
immunoreactive cells in islets and β-cell mass. (O to S) Glucose-stimulated insulin secretion in WT, ob/ob,
L/L, Lepr-siRNA transfected WT, and db/db islets treated with leptin in vitro. (T to V) Serum insulin levels
in Leprsyn−/−, Leprpomc−/− and Leprsf1−/− mice. Error bars, mean ± SEM. ∗∗, P < 0.01; ∗, P < 0.05; P1,
newborn; 1W, 1 week-old; 2W, 2 week-old; N.S., not significant; N.D, not detected.
model to study, in the absence of metabolic
abnormalities secondary to adiposity, mecha-
nisms whereby leptin regulates insulin secre-
tion. In 2-week-old ob/ob mice, serum insulin
levels were 2.5-fold higher than in wild-type
(WT) littermates, resulting in a more than 30%
decrease of blood glucose levels after feeding
(Fig. 1C and D). Remarkably, hyperinsuline-
mia and lower blood glucose levels were also
present in newborn and 1-week-old ob/ob mice
(Fig. 1C, D). These results established that lep-
tin is a physiological regulator of serum insulin
levels.
To understand how this severe hyperinsu-
linemia developed in mice otherwise metabol-
ically normal, we studied islet gene expression
and β-cell proliferation in 2-week-old WT and
ob/ob mice. While insulin sensitivity appeared
unaffected (Fig. S1B and C), expression of the
Insulin genes and of Glucokinase,8 a central com-
ponent of the glucose-sensing machinery of β-
cells, was increased 50% and 140%, respec-
tively, in ob/ob mice (Fig. 1E), accounting, at
least in part, for the increased insulin levels
described above. Serum c-peptide levels were
increased 2.5 fold in ob/ob mice (Fig. S2A).
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Insulin content was also increased, albeit not
significantly, in ob/ob pancreas (Fig. S3A). In ad-
dition, expression of Cdk4, a gene favoring β-cell
proliferation in vivo,9 was up-regulated 50% in
ob/ob islets, and Ki67 immunostaining showed
a significant increase in β-cell proliferation in
ob/ob compared with WT mice (Fig. 1E and F).
However, we could not detect an increase in
β-cell area and β-cell mass (Fig. S4). This lack
of increase in β-cell mass indicates that the ab-
sence of leptin affects circulating insulin levels
primarily by regulating insulin expression and
secretion in young ob/ob mice.
We asked if similar abnormalities were
present in young lipodystrophic mice
(adipocyte-deficient mice). Two-week-old
adipocyte-deficient mice were markedly
hyperinsulinemic and had a significant drop in
blood glucose levels; this hyperinsulinemia was
also observed at birth (Fig. 1G–J and Fig. S2B).
Expression of Insulin, Glucokinase, and Cdk4 was
up-regulated to the same extent in islets of
adipocyte-deficient and ob/ob mice (Fig. 1K).
Moreover, insulin content was significantly
increased in islets of adipocyte-deficient mice
(Fig. S3B). In addition, β-cell proliferation
measured by Ki67 immunostaining, β-cell
area, and β-cell mass was significantly in-
creased in lipodystrophic mice (Fig. 1L–N and
Fig. S5). Taken together, these data show that
hyperinsulinemia and lower blood glucose
levels precede the appearance of obesity and
hyperglycemia in ob/ob and adipocyte-deficient
mice, respectively, and can be ascribed, in
both cases, primarily to an increase in Insulin
and Glucokinase expression and, to a lesser
extent, to an increase in β-cell proliferation.
These results are consistent with the notion
that leptin inhibits in vivo insulin secretion.
That hyperinsulinemia is far more severe
in adipocyte-deficient than in ob/ob mice
indicates that other mechanisms in addition to
leptin deficiency affect insulin secretion in the
former model.
Next we tested the influence of leptin on in-
sulin secretion in isolated islets. Whether WT
islets were cultured in low or high glucose con-
centration, we did not observe a decrease in the
amount of insulin secreted in the medium fol-
lowing leptin treatment (Fig. 1O). When using
ob/ob islets leptin did decrease insulin secretion
(Fig. 1P), a result supporting the accepted no-
tion that it acts directly on β-cells to regulate in-
sulin secretion.1,2 However, this decrease never
reached statistical significance (n ≥ 10). Thus,
in the face of these results we asked whether
islets isolated from mice harboring an activat-
ing mutation in the leptin receptor (L/L mice)10
might be a better model to uncover a direct
effect of leptin on β-cells. In that case also we
failed to observe a significant decrease in insulin
secretion following leptin treatment (Fig. 1Q).
That insulin secretion was enhanced by high
glucose concentration indicates that the lack of
a statistically significant effect of leptin on in-
sulin secretion in these experiments was not due
to poor conditions of the islets. We also asked
whether leptin would affect glucose-stimulated
insulin secretion in islets that would not ex-
press its receptor. We first used siRNA to de-
crease Lepr expression, but failed to observe a
change in glucose-stimulated insulin secretion
after leptin treatment (Fig. 1R). Because siRNA
decreased Lepr expression only 50% (data not
shown), we were concerned that we did not
create the right conditions to perform this ex-
periment. Thus we also used islets isolated from
db/db mice that harbor an inactivating muta-
tion in the leptin receptor.11 As shown in Fig. 1S
leptin did not affect glucose-stimulated insulin
secretion by db/db islets either. Taken together,
data obtained through the use of islets isolated
from WT and ob/ob mice and from gain- and
loss-of-function mutations in the leptin receptor
are all consistent with the hypothesis that the
direct effect of leptin on β-cell may not be the
only mechanism whereby it regulates insulin
secretion.
In view of these results we asked whether
leptin uses a neuronal relay, in addition to its
direct effect on islets, to inhibit insulin secretion.
To that end we made use of a floxed allele of
the leptin receptor gene Lepr (Lepr-flox/flox).12
Deletion of the leptin receptor in all neurons
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through the use of Synapsin-Cre transgenic mice
resulted in a mouse model harboring a signifi-
cant increase in serum insulin levels (Fig. 1T).
This result established that there was indeed
a neuronal contribution to the leptin regula-
tion of insulin secretion. In light of this obser-
vation we studied the involvement of the ex-
pression of the leptin receptor in two neuronal
populations of the hypothalamus to the leptin
regulation of insulin secretion. Deletion of the
leptin receptor in arcuate neurons through the
use of Pomc-Cre transgenic mice did not affect
serum insulin levels (Fig. 1U). In contrast, delet-
ing it from ventromedial hypothalamic (VMH)
neurons through the use of Sf1-Cre transgenic
mice resulted in a nearly 2-fold increase in
serum insulin level in absence of insulin resis-
tance (Fig. 1V and Fig. S6). These results indi-
cate that VMH neurons contribute to the neu-
ronal pathway whereby leptin regulates insulin
secretion.
Since VMH neurons also contribute to lep-
tin regulation of sympathetic tone,13,14 we then
asked whether sympathetic tone could be a me-
diator of leptin-dependent central regulation
of insulin secretion.4,15 First we analyzed ex-
pression of all adrenergic receptors in islets.
Adrβ1 and Adrβ2 were by far the most highly
expressed; Adrα2A was also expressed, but at a
5-fold lower level. None of the other adrener-
gic receptors were detected in islets (Fig. S7).
Second, we treated WT, ob/ob, and adipocyte-
deficient newborn pups for 2 weeks with ei-
ther isoproterenol, a sympathomimetic acting
through β-adrenergic receptors; clonidine, a
sympathomimetic acting through the Adrα2
receptor; or, as a negative control, phenyle-
phrine, a sympathomimetic acting through the
Adrα1 receptor. As expected phenylephrine did
not affect serum insulin levels in any of the
mouse models tested, and clonidine had only
a marginal inhibitory effect (Fig. 2A). In con-
trast, isoproterenol decreased hyperinsulinemia
by more than half in ob/ob and adipocyte-
deficient but not in WT mice (Fig. 2A and B).
That Ucp1 expression was increased by isopro-
terenol supports the notion that there was an
increase in sympathetic tone as a result of this
treatment (Fig. S8). Remarkably, however, iso-
proterenol, like phenylephrine and clonidine
did not influence glucose-stimulated insulin se-
cretion from isolated islets maintained in either
low or high concentration of glucose (Fig. 2C).
Isoproterenol did not affect gene expression in
WT islets either (Fig. S9). Isoproterenol treat-
ment of ob/ob or L/L islets also failed to affect
glucose-stimulated insulin secretion (Fig. 2D
and E). Collectively, these observations indi-
cate that sympathetic tone acting through β-
adrenergic receptors regulates insulin secretion
but are inconsistent with a model whereby it
would do so by acting directly on islets.
The lack of a noticeable effect of isopro-
terenol on glucose-stimulated insulin secretion
in islets and the link between VMH neurons,
sympathetic tone, and bone mass, together with
the fact that Adrβ2 is the only adrenergic recep-
tor expressed in osteoblasts,13 were three facts
that led us to test the hypothesis that it was
through the osteoblasts that sympathetic tone,
under the control of leptin, regulates insulin
secretion. To test this hypothesis we analyzed
various mutant mouse strains each lacking one
adrenergic receptor. While serum insulin levels
were normal in Adrβ1−/− and Adnα2A−/− mice,
they were significantly higher in mice lack-
ing Adrβ2 in osteoblasts only (Adrβ2osb−/− mice)
than in WT mice (Fig. 2F–H and Fig. S10). This
abnormality developed in Adrβ2osb−/− mice in
the absence of insulin resistance (Fig. S11).
Adrβ2osb
−/− mice had also a 80% to 150% in-
crease in Insulin and Glucokinase expression and
exhibited postprandial low blood glucose lev-
els (Fig. 2I and J), all abnormalities observed in
ob/ob mice. Likewise, and as seen in ob/ob and
adipocyte-deficient mice, Cdk4 expression was
increased 50% in Adrβ2osb−/− mice (Fig. 2J and
Fig. S12A).
To establish formally that the increase
in insulin circulating levels noted in the
Adrβ2osb
−/− mice occurs under the control of
leptin, we generated ob/+;Adrβ2osb+/− com-
pound mutant mice. While both Adrβ2osb+/−
and ob/+ mice had normal serum insulin
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Figure 2. Sympathetic signaling in osteoblasts regulates insulin expression and secretion. (A and B)
Serum insulin levels in ob/ob and adipocyte-deficient mice after daily isoproterenol, phenylephrine, or
clonidine injection for 2 weeks. (C to E) Glucose-stimulated insulin secretion in WT, ob/ob, and L/L islets
treated with isoproterenol, phenylephrine, or clonidine in vitro. (F and G) Serum insulin levels in Adrβ1−/− or
Adrα2A−/− mice. (H to J) Serum insulin and blood glucose levels and gene expression in islets of 2-week-old
Adrβ2osb−/− mice. (K to M) Serum insulin, blood glucose, and Insulin expression in pancreas of 2-week-old
ob/+;Adrβ2osb+/− mice. (N) Delta insulin after glucose-stimulated insulin secretion in WT and Adrβ2osb−/−
mice treated with central leptin infusion at 4 ng/h for 1 week. (O and P) Plasma insulin levels during
hyperglycemic clamps in WT and Adrβ2osb−/− mice treated with central leptin infusion at 4 ng/h for 1 week.
Error bars, mean ± SEM; ∗∗, P < 0.01; ∗, P < 0.05. Control in H–J and M indicates α1(I)Collagen-Cre
mice.
levels, ob/+;Adrβ2osb+/− mice displayed hy-
perinsulinemia, lower blood glucose level af-
ter feeding, and increased Insulin expression
(Fig. 2K–M and Fig. S12B), as did Adrβ2osb−/−
and ob/ob mice. To further establish that sym-
pathetic tone in osteoblasts contributes to the
leptin regulation of insulin secretion, we per-
formed two additional experiments. First, long-
term (1 week) intracerebroventricular (ICV)
infusion of leptin (4 ng/h) decreased glucose-
stimulated insulin secretion in WT but not in
Adrβ2osb
−/− mice (Fig. 2N). This effect of lep-
tin was not observed when it was delivered
peripherally at that dose (data not shown).
Additionally, we performed a hyperglycemic
clamp to assess glucose-stimulated insulin se-
cretion in vivo. Similar to the previous ob-
servation, leptin ICV infusion during hyper-
glycemic clamps decreased circulating insulin
levels in WT but not Adrβ2osb−/− mice (Fig. 2O,
P). Taken together, these observations identify
sympathetic signaling in osteoblasts as a signif-
icant mediator of leptin’s regulation of insulin
secretion.
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Figure 3. Leptin regulates insulin secretion through osteoblasts. (A) Gene expression in isoproterenol- or
leptin-treated osteoblasts. (B) Levels of uncarboxylated osteocalcin (HA low affinity) in ob/ob and Adrβ2osb−/−
mice. (C) Insulin expression by HA-affinity fraction in islets. (D) Perifusion of WT islets in the presence of
osteocalcin (0.03 ng/mL) or KCl under 3 mM glucose condition. (E) Insulin secretion by osteocalcin in WT
islets maintained in low and high glucose. (F) Gene expression in osteocalcin-treated islets. (G to I) Serum
insulin and blood glucose in 2- to 8-week-old ob/ob;Esp+/− and ob/ob;Esp−/− mice. (J) GTT in 2-month-old
ob/ob;Esp−/− mice. (K) Serum insulin after glucose challenge in 2-month-old ob/ob;Esp−/− mice. (L and M)
Serum insulin and blood glucose in 2-week-old ob/ob;Ocn−/− mice. (N and O) Insulin/Ki67-positive cells and
gene expression in pancreas or islets of ob/ob;Ocn−/− mice. (P) Serum insulin in 2-week-old adp-def;Ocn−/−
mice. Error bars, mean ± SEM; ∗∗, P < 0.01; ∗, P < 0.05 Control in B indicates α1(I)Collagen-Cre mice.
How does sympathetic signaling in os-
teoblasts regulate insulin secretion in β-cells?
Osteoblasts secrete osteocalcin, a molecule
stimulating β-cell proliferation and Insulin ex-
pression, whose biological activity is decreased
by the product of the Esp gene.16 Multiple ob-
servations indicate that the leptin-dependent
sympathetic regulation of insulin secretion oc-
curs by modulating osteocalcin bioactivity.
Esp expression was up-regulated 4-fold by
isoproterenol in osteoblasts, while the expres-
sion of Osteocalcin and other enzymes modify-
ing it was not affected (Fig. 3A). Accordingly,
and although serum level of total osteocalcin
was normal (Fig. S13), the amount of osteocal-
cin binding to hydroxyapatite (HA) with low
affinity (that is, under-carboxylated and active
biologically16) was increased in both ob/ob and
Adrβ2osb
−/− mice (Fig. 3B). Two control exper-
iments validated this finding. First, when using
serum containing only uncarboxylated osteo-
calcin as a negative control, osteocalcin eluted
in the same fractions as the ones harboring an
increased content of osteocalcin in ob/ob serum
(data not shown). Second, the low-affinity frac-
tions could regulate Insulin expression in iso-
lated islets while the fractions binding to HA
with high affinity could not (Fig. 3C).
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TABLE 1. Insulin Sensitivity Analysis of 2-month-old ob/ob and ob/ob;Esp−/− Mice Analyzed by
Hyperinsulinemic-Euglycemic Clamps
Wild-type ob/ob ob/ob;Esp−/−
(n = 4) (n = 4) (n = 4)
Body weight (g) 17.8 ± 0.4 38.0 ± 1.7 31.5 ± 1.0
Glucose infusion rate (mg/kg/min) 64.9 ± 4.7 0.0 ± 0.0 0.0 ± 0.0
Basal hepatic glucose production (mg/kg/min) 15.9 ± 2.9 17.0 ± 1.2 15.1 ± 3.1
Clamp hepatic glucose production (mg/kg/min) −1.0 ± 4.2 20.7 ± 0.4 23.0 ± 1.6
Glucose turnover (mg/kg/min) 63.9 ± 2.5 20.7 ± 0.4 23.0 ± 1.6
Glycogen synthesis (mg/kg/min) 30.3 ± 1.9 4.4 ± 2.6 1.1 ± 0.4
Muscle glucose uptake (mL/kg/min) 65.4 ± 3.3 25.2 ± 5.7 22.3 ± 1.9
White adipose glucose uptake (mL/kg/min) 4.5 ± 0.9 1.2 ± 0.3 1.4 ± 0.2
Next we tested whether osteocalcin regulates
insulin secretion directly. In an islets perifusion
assay, osteocalcin (0.03 ng/mL) was a powerful
insulin secretagogue (Fig. 3D) with a strong first
phase and sustained, but lower, second phase
of insulin secretion in all experiments per-
formed. Osteocalcin also augmented glucose-
stimulated insulin secretion from isolated islets
maintained in either low or high glucose con-
centrations (Fig. 3E). Moreover, and unlike iso-
proterenol, osteocalcin treatment of isolated
islets increased expression of Insulin and Glucok-
inase (Fig. 3F). Insulin expression was induced
by osteocalcin in a concentration-dependent
manner,17 the effect was maximal at 4 h and
disappeared at 8 h (Fig. S14).
If osteocalcin is a mediator of the leptin-
dependent sympathetic regulation of insulin se-
cretion then increasing its bioactivity should
worsen hyperinsulinemia in ob/ob mice. To test
this contention we generated ob/ob mice lack-
ing one allele of Esp, the gene inhibiting os-
teocalcin bioactivity (ob/ob;Esp+/− mice) and
noticed in these mice a significant increase
in serum insulin levels when compared with
ob/ob mice (Fig. 3G). Since Esp+/− mice have
normal circulating insulin levels, this result es-
tablished the existence of a genetic interac-
tion between Leptin and Esp. We also gener-
ated ob/ob mice lacking both alleles of Esp
(ob/ob;Esp−/− mice). Most of these mutant
mice died with severe hypoglycemia within the
first few days of life (Fig. S15). The surviving
ob/ob;Esp−/− mice were two times more hy-
perinsulinemic than ob/ob mice at 2 weeks of
age. They also had low blood glucose levels
and remained significantly less glucose intol-
erant than ob/ob mice until 8 weeks of age,
illustrating the importance of this pathway in
adult animals (Fig. 3H–J and Fig. S16). Im-
proved glucose tolerance was demonstrated by
the ability of a glucose challenge to increase in-
sulin secretion in ob/ob;Esp−/− but not in ob/ob
mice (Fig. 3K), while insulin sensitivity, as mea-
sured by hyperinsulinemic-euglycemic clamps,
was similar in ob/ob;Esp−/− and ob/ob mice
(Table 1).
Lastly we tested the role of osteocalcin as
a mediator of leptin regulation of insulin se-
cretion. Mice lacking both Leptin and Osteo-
calcin (ob/ob;Osteocalcin−/−) had serum insulin
levels 50% lower than ob/ob mice and were
normoglycemic at 2 weeks of age (Fig. 3L
and M). Expression of Insulin, Glucokinase,
and Cdk4 was decreased 50% to 100% in
ob/ob;Osteocalcin−/− compared with ob/ob mice,
and β-cell proliferation was normalized in
ob/ob;Osteocalcin−/− mice (Fig. 3N and O). It
is worth noting that the correction of hyperin-
sulinemia was similar in isoproterenol-treated
ob/ob and ob/ob;Osteocalcin−/− mice, suggesting
that osteocalcin is a mediator of the leptin-
dependent sympathetic regulation of insulin
secretion. In addition, osteocalcin deletion in
adipocyte-deficient mice decreased their serum
insulin levels by half (Fig. 3P). Taken together,
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Figure 4. Sympathetic tone regulates osteocalcin bioactivity through Atf4. (A) Esp promoter activity in
ROS17/2.8 osteoblasts. (B and C) Cotransfection assay in COS cells using Esp promoter and indicated
expression vectors. (D) ChIP assay in osteoblasts. (E) Esp promoter activity in ROS17/2.8 osteoblasts treated
with isoproterenol (10 μM). (F and G) Serum insulin and blood glucose levels in Crebosb−/− and Atf4−/−
mice at indicated ages. (H) GTT in 2-month-old Atf4−/− mice. (I) Insulin/Ki67-positive cells in islets of WT,
Crebosb−/−, and Atf4−/− mice. (J and K) Total and uncarboxylated (HA low affinity) osteocalcin levels in
Atf4−/− mice. (L to N) Serum insulin, blood glucose levels and insulin/Ki67-immunoreactive cells in islets of
Adrβ2osb+/−;Atf4+/− mice. (O) Gene expression in islets treated with osteocalcin for 2 h. (P) Phosphorylation
of CREB in osteocalcin-treated β-cells. (Q) ChIP assay in β-cells. Error bars, mean ± SEM; ∗∗, P < 0.01;
∗, P < 0.05.
these results support the hypothesis that the
leptin-dependent sympathetic regulation of in-
sulin secretion occurs via the osteoblast and
uses osteocalcin as its mediator. Although we
do not know at present how Esp modulates
osteocalcin carboxylation, the most likely ex-
planation is that it affects the activity of gamma
carboxylase, the enzyme necessary for carboxy-
lation of osteocalcin, through an indirect mech-
anism since this enzyme is not phosphorylated
(data not shown).
How does sympathetic tone regulate Esp ex-
pression and osteocalcin bioactivity? Esp con-
tains a cAMP-responsive element (CRE) at
−340 bp that is required, in cell-based as-
says, for osteoblast-specific and sympathetic-
dependent activity of this promoter fragment
(Fig. 4A–C and E). Chromatin immunoprecip-
itation assays demonstrated that this CRE is
not occupied by CREB itself, but by ATF4,
an osteoblast-specific member of the CREB
family whose activity is regulated by PKA
(Fig. 4D).18 The functional relevance of ATF4
binding to the Esp promoter in regulating
glucose metabolism was documented in vivo.
Atf4−/− mice exhibited significant postprandial
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hyperinsulinemia and low blood glucose level,
along with an increase in glucose tolerance and
β-cell proliferation (Fig. 4F–I). In contrast none
of these abnormalities was observed in mice
lacking CREB in osteoblasts only (Fig. 4F, G
and I and Fig. S17). Atf4−/− mice also displayed
a relative increase in the percentage of uncar-
boxylated (i.e., bioactive) osteocalcin, despite
the fact that total osteocalcin blood levels were
lower in these mice, an expected finding since
ATF4 regulates Osteocalcin expression (Fig. 4J,
K).18 To provide evidence that Atf4 mediates
the sympathetic regulation of insulin secretion
through its expression in osteoblasts, we gener-
ated compound heterozygous mice lacking, in
osteoblasts, one copy of Adrβ2 and one copy of
Atf4. These Adrβ2osb+/−;Atf4+/− mice showed
a doubling in circulating insulin levels leading
to hypoglycemia and an increase in β-cell pro-
liferation, all features comparable to what was
observed in ob/ob mice (Fig. 4L–N). To address
the molecular mechanisms used by osteocalcin
to regulate insulin expression and secretion, we
studied expression of genes encoding transcrip-
tion factors regulating Insulin and Glucokinase.19
As shown here osteocalcin induced within 2 h
expression of Creb and NeuroD, two well-known
regulators of Insulin expression19 (Fig. 4O). Os-
teocalcin treatment also increased phosphory-
lation of CREB, an event necessary for its tran-
scriptional activity, and binding of NeuroD to
its cognate sequence on the insulin promoter
(Fig. 4P and Q).20 Besides NeuroD and Creb, os-
teocalcin treatment of β-cells also enhanced ex-
pression of Pparγ (Fig. 4O), a known regulator
of glucokinase expression.21
Taken together the in vivo data presented here
(Table S1) indicate that for approximately half
of it leptin’s inhibition of insulin secretion relies
on a 3-step cascade including: i) leptin’s up-
regulation of sympathetic tone, ii) sympathetic
enhancement of Esp expression in osteoblasts,
and iii) decrease in osteocalcin bioactivity. Our
results do not deny that leptin can act directly
on β-cells to regulate insulin secretion; instead
they point toward an additional mechanism ac-
counting for leptin regulation of insulin secre-
tion in vivo. This mechanism of action relies, as
it is the case for other functions of leptin,22,23
on a central relay, but also includes another
target organ of leptin, namely, bone. The ab-
sence of increase in β-cell mass in young ob/ob
mice suggests that osteocalcin acts in this con-
text primarily by regulating insulin expression
and secretion. Beyond the leptin/sympathetic,
tone/osteocalcin/insulin cascade, these results
establish that the metabolic connection be-
tween adipocytes and osteoblasts recently un-
covered is not limited to cross-regulation.16,24,25
Rather, this cross-talk includes, as an impor-
tant component, the use by adipocytes of os-
teoblasts to mediate a significant part of one
of their endocrine functions on β-cells. This
unexpected functional relationship between
adipocytes, sympathetic tone, and osteoblasts
illustrates in vivo the importance of the skele-
ton in regulating insulin secretion and glucose
homeostasis.
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